گروه تحقیق و توسعه زیست فناوری نوژن

The company, founded by pioneers of the rapid test industry, has developed a proprietary patented immunoassay platform enabling the development of qualitative and multiplex point of care diagnostics. Results are obtained in few minutes from a single drop of blood (or any other type of sample). NG Biotech sells a range of CE marked rapid tests Worldwide. Product validations are performed in comparison to laboratory standard reference methods such as Elisa or HPLC. The company is ISO 13485:2016 certified. Current production capacity is of more than 4 million tests per month. At NG Biotech we support our partners’ Innovation meeting their screening and monitoring needs; we develop new solutions for their applications. Targeted areas are m-Health, Companion and Medical Diagnostics. We also cover Animal Health, Agriculture and Biodefense among others. We put our know-how and expertise in product development, manufacturing and product registration at your service. Missions – NG Biotech develops, manufactures and markets in vitro diagnostics for screening, diagnosis, monitoring and prevention with the intention to improve outcome of disease management. – We focus on urgency of decision making processes with rapid and easy to use tests providing quicker support to healthcare professionals and patients. NG Biotech was founded in 2012 by 3 pioneers in rapid tests industry. The company capitalizes on the expertise of a great team to become a global leader in its industry. Located in Guipry-Messac in France, NG Biotech has two 5,000 m2 industrial sites that comply with international standards, enabling to integrate and manage all steps of design, development and production of its products, to ensure worldwide registration (CE marking, FDA, etc.), and to design custom tests for major international players. NG Biotech aims at providing products that meet customer and regulatory requirements, with the commitment to improve customer satisfaction through the effective application of